CDK inhibitor– tag –
-
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 5: CDK11 — Pause-Checkpoint and Emerging Therapeutic Potential)
In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. Here in Part 5, we focus on CDK11, a kinase that has recently gained attention for its role as a pause-checkpoint regulator in transcription, preceding... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 4: CDK12 & CDK13 — DNA Repair and Synthetic Lethality Strategies)
In Parts 1–3, we reviewed CDK7/8 and CDK9. Here in Part 4, we turn to CDK12 and CDK13, transcriptional kinases that stabilize elongation of long DNA repair genes. They serve as “guardians” of genome stability and represent key players in... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 3: CDK9 — The Bottleneck of Transcription Elongation and Clinical Development)
In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. Here in Part 3, we focus on CDK9, the central kinase controlling the transition from paused RNA polymerase II (Pol II) to productive elongation. Among transcripti... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 2: CDK7 & CDK8 — Gatekeepers of Transcription Initiation and Emerging Therapeutics)
In Part 1, we reviewed the fundamentals of transcription and the CDK family. In this article, we focus on CDK7 and CDK8, two kinases that act at the transcriptional “starting line.” While both regulate initiation, their roles and drug di...
1